Cremophor News and Research

RSS

Cremophor is an emulsifying agent for the pharmaceuticals, cosmetics and feedstuffs industries; used in aqueous preparations of hydrophobic substances, e.g. fat-soluble vitamins and essential oils.

New method to develop nanoengineered bacteria for photothermal cancer immunotheranostics

There is substantial interest regarding the understanding and designing of nanoengineered bacteria to combat various fatal cancerous diseases.

22 Feb 2022

Scientists use novel technology for opening blood-brain barrier with implantable ultrasound

One of most potent drugs for treatment of glioblastoma, the most deadly type of brain tumor, can't be used in patients because of two problems. First, it can't reach its target because it's blocked by the blood-brain barrier, a microscopic structure that protects the brain from toxins in the blood. And the conventional formulation for this drug is toxic to the brain.

12 Dec 2019

Oasmia announces topline results from head-to-head comparison study of Paclical and Abraxane

Oasmia Pharmaceutical AB, developer of a new generation of drugs within human and veterinary oncology, announced today the topline findings from a head-to-head comparison study of its lead human cancer product candidate Paclical and Celgene's Abraxane, which show similar pharmacokinetic (PK) profiles of the two products. The study was conducted in women with metastatic breast cancer.

4 Aug 2015

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.

21 Jun 2013

Sorrento Therapeutics, IGDRASOL announce publication of clinical data for Cynviloq and gemcitabine

Sorrento Therapeutics, Inc. and IGDRASOL announced today that clinical data for CynviloqTM, a non-biologic nanoparticle formulation of paclitaxel, plus gemcitabine was published for the upcoming Annual Meeting of the American Society of Clinical Oncology.

28 May 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its development of Cynviloq (IG-001) at the annual meeting of the American Association for Cancer Research in Washington, DC (April 6th to 10th).

1 Apr 2013

NeuroVive announce results from CicloMulsion Phase I trial on cardiac reperfusion injury

NeuroVive announces publication of the results of a Phase I clinical trial of lead product CicloMulsion in the scientific journal Clinical Drug Investigation. The paper highlights that the intravenous cyclosporine formulation CicloMulsion demonstrates bioequivalence and improved tolerability when compared with Sandimmune Injection.

3 Dec 2012

Researchers test nanoscale carbon clusters for cancer chemotherapy

A mixture of current drugs and carbon nanoparticles shows potential to enhance treatment for head-and-neck cancers, especially when combined with radiation therapy, according to new research by Rice University and the University of Texas MD Anderson Cancer Center.

16 Feb 2012

Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial

NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM) cremophor-free IV cyclosporine formulation is used in this study of 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.

20 Apr 2011

NeuroVive, HCL initiate CicloMulsion Phase III trial in myocardial infarction

NeuroVive Pharmaceutical and Hospices Civils de Lyon today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction.

19 Apr 2011

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol (paclitaxel) injection plus carboplatin in the first-line treatment of patients with non-small cell lung cancer.

8 Jun 2010

Cremophor-based paclitaxel ‘chemo’ drug triggers fatal allergic reactions

A chemotherapy drug that is supposed to help save cancer patients' lives, instead resulted in life-threatening and sometimes fatal allergic reactions.

9 Jun 2009

FDA approves approved Ixempra (ixabepilone) for advanced breast cancer

The U.S. Food and Drug Administration has approved Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs.

22 Oct 2007

New York Times examines efforts to obtain FDA approval for Abraxane to treat earlier-stage cancer

The New York Times has examined efforts by the pharmaceutical company Abraxis BioScience to obtain FDA approval for its late-stage breast cancer drug Abraxane as a treatment for earlier-stage breast cancer.

5 Oct 2006

Abraxane, first in a new class of albumin-bound nanotechnology for the treatment of metastatic breast cancer

Abraxane (paclitaxel protein-bound particles for injectable suspension), a next generation taxane, and the first in a new class of albumin-bound nanotechnology, was approved for the treatment of metastatic breast cancer.

9 Jan 2005

Promising new cancer drug, Nanotax

A Lawrence company that uses patented technology created at the University of Kansas to improve the effectiveness of drugs has won a $100,000 National Institutes of Health grant to support further testing of the company's promising new cancer drug, Nanotax.

5 Aug 2004